Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine最新文献_第2页

High efficiency of CD34+ selection by removal of platelets from the apheresis product. 通过从分离产物中去除血小板，CD34+选择效率高。

Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine Pub Date : 1997-01-01

T Schreiner, B Maccari, E Erne, C Bischof, M Wiesneth

引用次数: 0

CMV-induced anti-Sia-b1 cold agglutinin in an immunocompromised patient. cmv诱导的免疫功能低下患者的抗sia -b1冷凝集素。

Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine Pub Date : 1997-01-01

G Zilow, D Haffner, D Roelcke

引用次数: 0

[Intrauterine transfusion in fetal alloimmunothrombocytopenia: comparison of maternal and fetal weight-adjusted IgG therapy with exclusive fetal thrombocyte transfusion]. [宫内输血治疗胎儿同种异体免疫血小板减少症:母体和胎儿体重调节IgG治疗与胎儿单独输血的比较]。

Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine Pub Date : 1997-01-01

G Giers, H Kroll, J Hoch, R Bald, H Bauer, V Kiefel, M Hansmann, P Hanfland, C Mueller-Eckhardt, R E Scharf

引用次数: 0

[Anti-hepatitis C prevalence and incidence in 2.8 million blood donors in Lower Saxony--residual transfusion-associated HCV risk]. [下萨克森州280万献血者抗丙型肝炎流行率和发病率——与输血相关的残留丙型肝炎风险]。

Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine Pub Date : 1997-01-01

U Diekamp, K Kamutzky, C D Windel

{"title":"[Anti-hepatitis C prevalence and incidence in 2.8 million blood donors in Lower Saxony--residual transfusion-associated HCV risk].","authors":"U Diekamp, K Kamutzky, C D Windel","doi":"","DOIUrl":"","url":null,"abstract":"561 out of 2,777,021 blood donations from 582,655 donors tested confirmed positive for anti-HCV (RIBA II or Matrix Dot), 549 of them at their first donation, in their first HCV test ever, or in the first HCV test with a new, more sensitive test generation. Thus, our anti-HCV prevalence is 0.037% or 1 in 2,679 donations; among first-time donations it is five times higher than among repeat donations. Twelve repeat donors seroconverted, yielding an anti-HCV incidence of 0.0008% or 1 in 122,570 repeat donations and a seroconversion rate of 2.32 per 10(5) repeat donor person-years. The residual risk associated with transfusion of blood for repeat donors amounts to 5.2 per 10(6) repeat donations. We estimate a risk reduction from introduction of direct virus genome testing after PCR to be at 3.7 per 10(6) repeat donations. Look-backs among recipients of the last seronegative blood products from 12 donors with subsequent seroconversion revealed no recipient infection. Thus, today the residual risk for HCV transmission through transfusion of blood components obtained from Lower Saxony blood donors is quite low. The added safety from direct virus genome testing after PCR is considered extremely low, which casts doubt on the cost-effectiveness of such a measure.","PeriodicalId":79439,"journal":{"name":"Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine","volume":"34 ","pages":"5-10"},"PeriodicalIF":0.0,"publicationDate":"1997-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20345195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Preparation of leukocyte depleted thrombocytapheresis preparations using closed disposable systems with an in-line filter for the AS 104 cell separator]. [使用带AS 104细胞分离器在线过滤器的封闭式一次性系统制备白细胞耗尽血小板分离制剂]。

Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine Pub Date : 1997-01-01

R Moog, R Kalb, N Müller, A C Köbke

引用次数: 0

Allele-specific PCR amplification of factor V Leiden to identify patients at risk for thromboembolism. Leiden因子等位基因特异性PCR扩增识别血栓栓塞危险患者。

Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine Pub Date : 1997-01-01

R Blasczyk, J Wehling, M Ritter, A Neubauer, H Riess

{"title":"Allele-specific PCR amplification of factor V Leiden to identify patients at risk for thromboembolism.","authors":"R Blasczyk, J Wehling, M Ritter, A Neubauer, H Riess","doi":"","DOIUrl":"","url":null,"abstract":"Resistance to activated protein C is the most common hereditary cause of thrombophilia and is significantly linked to factor V Leiden. We designed primers in order to identify factor V Leiden by allele-specific PCR amplification. Amplification specificity for factor V was ensured by a 3' primer located at the intron 9/exon 10 border of the gene. One sense and two antisense primers were used in two separate primer mixes specific for factor V ARG506 (wild-type) or factor V GLN506 (factor V Leiden). In each PCR reaction a pair of primers amplifying a fragment of the human growth hormone gene was included as an internal positive amplification control. The presence or absence of specific PCR amplification allowed definite allele assignment without the need for any postamplification specificity step. The internal positive control primers indicate a successful PCR amplification, allowing the assignment of homozygosity. In a prospective study 126 patients with thromboembolic events were analyzed using this technique and PCR-RFLP. The concordance between these methods was 100%. In 27 patients a heterozygous factor V GLN506 mutation was detected, whereas 1 patient with recurrent thromboembolism was homozygous. No false-positive or false-negative results were observed in the homozygous as well as heterozygous samples. Additionally, in 15 samples identified to carry the point mutation by allele-specific PCR amplification, automatic sequencing has confirmed the heterozygous or homozygous point mutation. Due to its time- and cost-saving features allele-specific amplification should be considered for screening of factor V Leiden.","PeriodicalId":79439,"journal":{"name":"Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine","volume":"34 ","pages":"236-41"},"PeriodicalIF":0.0,"publicationDate":"1997-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20287286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Effect of whole blood preparation and leukocyte filtration on storage of erythrocyte concentrates over 42 days]. [全血制备和白细胞过滤对红细胞浓缩物42 d以上储存的影响]。

Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine Pub Date : 1997-01-01

M Müller-Steinhardt, K Janetzko, H Kirchner, H Klüter

{"title":"[Effect of whole blood preparation and leukocyte filtration on storage of erythrocyte concentrates over 42 days].","authors":"M Müller-Steinhardt, K Janetzko, H Kirchner, H Klüter","doi":"","DOIUrl":"","url":null,"abstract":"Leukocyte reduction prior to storage of red cell concentrates (RCC) may reduce the incidence of HLA alloimmunization and may improve the quality of stored RCC. We tested an RCC leukoreduction filter system (Baxter) with an integrated Pall RCM-1 filter and investigated the filtration efficiency and the impact on red cells during storage for 42 days after different whole-blood preparation procedures. After whole-blood donation, all units (n = 9, +6 unfiltered controls per group) were either stored at 22 degrees C for up to 6 h (groups 1, 2, 3) or for 24 h (group 4) RCC were either prepared from a triple blood bag system (PL 146, groups 1, 2) or were buffy-coat-depleted (PL 2209, groups 3, 4). Groups 1, 3 und 4 were filtered immediately, whereas group 2 was stored another 18 h at 4 degrees C before filtration. Filtration efficiency and filtration time were determined. Hemolysis, ATP, 2,3-diphosphoglycerate (2,3-DPG), glucose, electrolytes, lactate, hematocrit, Hb and pH were quantified weekly. White blood cells (WBC) were reduced by 3-4 log10 to 0.1-0.3 x 10(6) (mean) by filtration (all groups) regardless of the RCC preparation. Mean filtration times were 1 h 36 min, 33 min, 29 min, and 18 min for the groups 1 to 4, respectively. There were no major differences for the in vitro storage values except for hemolysis and pH, which were elevated in all filtered units, and potassium, which was elevated in the unifiltered units. In conclusion, prestorage leukocyte filtration of RCC reduced the WBC by 3-4 log10, whereas the extended filtration time was a major disadvantage.","PeriodicalId":79439,"journal":{"name":"Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine","volume":"34 ","pages":"53-7"},"PeriodicalIF":0.0,"publicationDate":"1997-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20345196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Specific Lp(a) apheresis for secondary prevention of arteriosclerosis]. [特异性Lp(a)采血二级预防动脉硬化]。

Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine Pub Date : 1997-01-01

H Ullrich, B G Matic, K J Lackner, G Rothe, G Schmitz

{"title":"[Specific Lp(a) apheresis for secondary prevention of arteriosclerosis].","authors":"H Ullrich, B G Matic, K J Lackner, G Rothe, G Schmitz","doi":"","DOIUrl":"","url":null,"abstract":"Lipoprotein(a) (Lp(a)) is an independent risk factor for arteriosclerosis. It consists of the Lp(a)-specific apo(a) which is bound to the apo-B of an LDL particle by a disulfide bridge. Apo(a) is homologous to parts of the plasminogen molecule: It consists of one kringle 5 and 10-40 kringles 4 of the plasminogen molecule. Due to the lack of alternative drug treatment, 3 patients with early onset of arteriosclerosis, rapid progression, and elevated Lp(a) as their dominating risk factor were treated weekly with specific Lp(a)-aphereses. Since October 1992, we carried out 229 immunoadsorptions (IA) with specific columns containing anti-Lp(a) antibodies covalently bound to sepharose. To reduce Lp(a) from preapheresis values of 142 +/- 53 mg/dl to 25 +/- 11 mg/dl immediately after apheresis, we had to adsorb 1.4-3 patient's plasma volumes. Lp(a) rise to preapheresis values took 3-4 days. Protein reduction caused by loss of plasma during column changes remained tolerable (total protein before IA: 71 +/- 4 g/l, after IA: 56 +/- 4 g/l. Immediately after IA, these values were measured after the application of 991 +/- 207 ml of ACDB with 5,000 IU of heparin as anticoagulant. Hemoglobin remained unchanged (before IA: 13.4 +/- 1.4 g/dl, after IA: 13.6 +/- 1.5 g/dl). Side effects were mainly flush and tachycardia. They were seen especially when using new columns and plasma flow rates above 55 ml/min and were immediately reverted by interrupting the IA. Control angiography performed after 2 years in 2 patients showed no progression of disease, in the 3rd patient, the stress test showed a significant improvement as did clinical parameters. In our hands, IAs are a safe and efficient method for Lp(a) reduction and secondary prevention of myocardial infarction. Therapeutic efficiency should further be proven by a controlled trial.","PeriodicalId":79439,"journal":{"name":"Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine","volume":"34 ","pages":"248-55"},"PeriodicalIF":0.0,"publicationDate":"1997-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20346634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rapid donor type isoagglutinin production after allogeneic peripheral progenitor cell transplantation. 异体外周祖细胞移植后供体型异凝集素的快速产生。

Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine Pub Date : 1997-01-01

R Moog, C Melder, M Prumbaum, N Müller, U W Schaefer

引用次数: 0

Limits of the MAIPA assay when differentiating high-titered platelet-reactive antibodies. MAIPA法鉴别高滴度血小板反应性抗体的局限性。

Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine Pub Date : 1997-01-01

A Agildere, D Wernet, M Schnaidt

引用次数: 0